| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer | President & CEO
3 companies
John L Higgins is Director at OABI and has filed Form 4s across 3 companies. From February 2015 to October 2026, the filings on record show 8 open-market purchases and 34 sales. The disclosed holdings are worth an estimated $27.7M at current prices.
Historically, John L Higgins's trades have earned a middling insider score of 66/100 across 18 rated trades. Over a 12-month horizon, 60.0% of those trades were profitable, with an average 12-month return of +8.8%.
The biggest single holding is LGND (~$27.7M) as Director. The LGND filings lean toward selling, a net 341,329 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2015 | LGND Ligand Pharmaceuticals Inc | Chief Executive Officer | Sell | 4,666 | $110.79 | $516,946.14 | -3.7% | |
| Jun 9, 2015 | LGND Ligand Pharmaceuticals Inc | Chief Executive Officer | Sell | 10,000 | $92.88 | $928,809.00 | -7.4% |